These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Clinical utility and patient perspectives on the use of extended half-life rFIXFc in the management of hemophilia B. Miguelino MG; Powell JS Patient Prefer Adherence; 2014; 8():1073-83. PubMed ID: 25143713 [TBL] [Abstract][Full Text] [Related]
4. Alprolix (recombinant Factor IX Fc fusion protein): extended half-life product for the prophylaxis and treatment of hemophilia B. Ducore JM; Miguelino MG; Powell JS Expert Rev Hematol; 2014 Oct; 7(5):559-71. PubMed ID: 25142322 [TBL] [Abstract][Full Text] [Related]
5. Development of long-acting recombinant FVIII and FIX Fc fusion proteins for the management of hemophilia. Shapiro A Expert Opin Biol Ther; 2013 Sep; 13(9):1287-97. PubMed ID: 23930915 [TBL] [Abstract][Full Text] [Related]
6. The old and new: PCCs, VIIa, and long-lasting clotting factors for hemophilia and other bleeding disorders. Ragni MV Hematology Am Soc Hematol Educ Program; 2013; 2013():44-51. PubMed ID: 24319161 [TBL] [Abstract][Full Text] [Related]
7. Emerging drugs for hemophilia B. Mannucci PM; Franchini M Expert Opin Emerg Drugs; 2014 Sep; 19(3):407-14. PubMed ID: 25098797 [TBL] [Abstract][Full Text] [Related]
8. Recent advances in the development of coagulation factors and procoagulants for the treatment of hemophilia. Schaub RG Biochem Pharmacol; 2011 Jul; 82(2):91-8. PubMed ID: 21453683 [TBL] [Abstract][Full Text] [Related]
9. Innovative coagulation factors: albumin fusion technology and recombinant single-chain factor VIII. Schulte S Thromb Res; 2013 Mar; 131 Suppl 2():S2-6. PubMed ID: 23537723 [TBL] [Abstract][Full Text] [Related]
10. Prophylaxis for Hemophilia in the Era of Extended Half-Life Factor VIII/Factor IX Products. Berntorp E; Andersson NG Semin Thromb Hemost; 2016 Jul; 42(5):518-25. PubMed ID: 27096762 [TBL] [Abstract][Full Text] [Related]
11. Molecular approaches for improved clotting factors for hemophilia. Kaufman RJ; Powell JS Hematology Am Soc Hematol Educ Program; 2013; 2013():30-6. PubMed ID: 24319159 [TBL] [Abstract][Full Text] [Related]
12. New products for the treatment of haemophilia. Laffan M Br J Haematol; 2016 Jan; 172(1):23-31. PubMed ID: 26456702 [TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of coagulation factors: clinical relevance for patients with haemophilia. Björkman S; Berntorp E Clin Pharmacokinet; 2001; 40(11):815-32. PubMed ID: 11735604 [TBL] [Abstract][Full Text] [Related]
14. 2017 Clinical trials update: Innovations in hemophilia therapy. Hartmann J; Croteau SE Am J Hematol; 2016 Dec; 91(12):1252-1260. PubMed ID: 27563744 [TBL] [Abstract][Full Text] [Related]
15. Current management of hemophilia B: recommendations, complications and emerging issues. Franchini M Expert Rev Hematol; 2014 Oct; 7(5):573-81. PubMed ID: 25112898 [TBL] [Abstract][Full Text] [Related]
18. Novel products for haemostasis - current status. Oldenburg J; Albert T Haemophilia; 2014 May; 20 Suppl 4():23-8. PubMed ID: 24762271 [TBL] [Abstract][Full Text] [Related]
19. Expression and characterization of a novel human recombinant factor IX molecule with enhanced in vitro and in vivo clotting activity. Perot E; Enjolras N; Le Quellec S; Indalecio A; Girard J; Negrier C; Dargaud Y Thromb Res; 2015 May; 135(5):1017-24. PubMed ID: 25795563 [TBL] [Abstract][Full Text] [Related]